Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Novavax Completes Enrollment in Phase I/IIa Influenza Vaccine Trial
RxTrials Institute Drug Pipeline Alert
May 21, 2008 | Vol. 6 No. 21
Novavax Completes Enrollment in Phase I/IIa Influenza Vaccine Trial
Novavax has enrolled roughly 230 subjects in its Phase I/IIa study of its pandemic influenza vaccine.
Interim findings last December suggested that the vaccine was well tolerated in 70 healthy adults, according to the company.
Based upon its review of these findings, the data and safety monitoring board recommended that the study continue. Results for the upcoming trial are expected in the third quarter of this year.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.